Nonchemotherapeutic therapies such as tyrosine kinase inhibitors are proving valuable in children and adolescents with acute lymphoblastic leukemia, according to a recent review. The authors note that although current treatments confer favorable prognosis, multiagent chemotherapy regimens are linked with complications, and therapy for relapsed disease is intensive and often not optimal.
The review goes on to summarize promising results from recent clinical trials of novel nonchemotherapeutic treatments, which can be used in conjunction with, or even in place of, current regimens.
Silverman L. Incorporation of nonchemotherapeutic agents in pediatric acute lymphoblastic leukemia. Hematology 2017. 2017;2017(1):259-264. doi:10.1182/asheducation-2017.1.259.
This Week's Must Reads
Must Reads in Hematologic Malignancies
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10
Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al
These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al
Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al
The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al